EPHA5
Ephrin type-A receptor 5
Also known as: CEK7, EHK1, EPHA5_HUMAN, Hek7, TYRO4
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P54756
- Gene
- EPHA5
- Ensembl
- ENSG00000145242
- Chromosome
- 4
- Canonical length
- 1037 aa
- Protein class
- Enzymes, Predicted membrane proteins
- Subcellular location
- Golgi apparatus,Vesicles,Plasma membrane
OverviewNCBI Gene
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Aug 2013]
Canonical amino-acid sequenceUniProt
1037 residues, UniProt reviewed canonical sequence.
>P54756|EPHA5
1 MRGSGPRGAG RRRPPSGGGD TPITPASLAG CYSAPRRAPL WTCLLLCAAL RTLLASPSNE
61 VNLLDSRTVM GDLGWIAFPK NGWEEIGEVD ENYAPIHTYQ VCKVMEQNQN NWLLTSWISN
121 EGASRIFIEL KFTLRDCNSL PGGLGTCKET FNMYYFESDD QNGRNIKENQ YIKIDTIAAD
181 ESFTELDLGD RVMKLNTEVR DVGPLSKKGF YLAFQDVGAC IALVSVRVYY KKCPSVVRHL
241 AVFPDTITGA DSSQLLEVSG SCVNHSVTDE PPKMHCSAEG EWLVPIGKCM CKAGYEEKNG
301 TCQVCRPGFF KASPHIQSCG KCPPHSYTHE EASTSCVCEK DYFRRESDPP TMACTRPPSA
361 PRNAISNVNE TSVFLEWIPP ADTGGRKDVS YYIACKKCNS HAGVCEECGG HVRYLPRQSG
421 LKNTSVMMVD LLAHTNYTFE IEAVNGVSDL SPGARQYVSV NVTTNQAAPS PVTNVKKGKI
481 AKNSISLSWQ EPDRPNGIIL EYEIKYFEKD QETSYTIIKS KETTITAEGL KPASVYVFQI
541 RARTAAGYGV FSRRFEFETT PVFAASSDQS QIPVIAVSVT VGVILLAVVI GVLLSGSCCE
601 CGCGRASSLC AVAHPSLIWR CGYSKAKQDP EEEKMHFHNG HIKLPGVRTY IDPHTYEDPN
661 QAVHEFAKEI EASCITIERV IGAGEFGEVC SGRLKLPGKR ELPVAIKTLK VGYTEKQRRD
721 FLGEASIMGQ FDHPNIIHLE GVVTKSKPVM IVTEYMENGS LDTFLKKNDG QFTVIQLVGM
781 LRGISAGMKY LSDMGYVHRD LAARNILINS NLVCKVSDFG LSRVLEDDPE AAYTTRGGKI
841 PIRWTAPEAI AFRKFTSASD VWSYGIVMWE VVSYGERPYW EMTNQDVIKA VEEGYRLPSP
901 MDCPAALYQL MLDCWQKERN SRPKFDEIVN MLDKLIRNPS SLKTLVNASC RVSNLLAEHS
961 PLGSGAYRSV GEWLEAIKMG RYTEIFMENG YSSMDAVAQV TLEDLRRLGV TLVGHQKKIM
1021 NSLQEMKVQL VNGMVPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EPHA5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.34
- Highest tissue expression
- 11 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 11 nTPM
- hippocampal formation: 4.8 nTPM
- amygdala: 3 nTPM
- hypothalamus: 2.5 nTPM
- cervix: 1.9 nTPM
- midbrain: 1.7 nTPM
Single-cell type
- brain excitatory neurons: 296 nCPM
- prostatic glandular cells: 290 nCPM
- lactotrophs: 275 nCPM
- retinal ganglion cells: 259 nCPM
- other brain neurons: 206 nCPM
- brain inhibitory neurons: 138 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 62 nTPM
- hippocampal formation: 49 nTPM
- pons: 23 nTPM
- white matter: 21 nTPM
- basal ganglia: 21 nTPM
- hypothalamus: 20 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.52
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.36
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- axon guidance
- ephrin receptor signaling pathway
- hippocampus development
- neuron development
- positive regulation of CREB transcription factor activity
- regulation of actin cytoskeleton organization
- regulation of GTPase activity
- regulation of insulin secretion involved in cellular response to glucose stimulus
Molecular functions
- ATP binding
- ephrin receptor activity
- GPI-linked ephrin receptor activity
- transmembrane-ephrin receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Ephrin, ligand binding domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Tyrosine-protein kinase, receptor class V, conserved site
- Sterile alpha motif domain
- Fibronectin type III
- Tyrosine-protein kinase, active site
- Galactose-binding-like domain superfamily
- Protein kinase-like domain superfamily
- Sterile alpha motif/pointed domain superfamily
- Immunoglobulin-like fold
- Ephrin receptor type-A /type-B
- Protein kinase, ATP binding site
- Tyrosine-protein kinase, catalytic domain
- Ephrin, transmembrane domain
- Fibronectin type III superfamily
- Ephrin receptor tyrosine kinases
- Fibronectin type III domain
- SAM domain (Sterile alpha motif)
- Ephrin receptor ligand binding domain
- Protein tyrosine and serine/threonine kinase
- Ephrin type-A receptor 2 transmembrane domain
- Ephrin cysteine rich domain
- Ephrin type-A receptor 5, ligand binding domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EPHA5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EPHA5 as an antibody target. Whether an autoantibody or antibody against EPHA5 could matter depends on whether native EPHA5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EPHA5 is annotated at the cell surface, where native EPHA5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label EPHA5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...